C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$0.71 revenue$3,759,000

Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.
R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.
Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.
Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.
IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $3.8 million, net income $34.8 million, EPS $0.71.

Period: the first quarter ended March 31, 2023
Revenue: $3.8 million
Net income: $34.8 million
EPS: $0.71
Result: reported results

Exact text from the filing

will participate in the Jefferies Global Healthcare Conference in New York. FIRST QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and

View on SEC.gov

Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.